Novo Nordisk Invests Over $8 Billion to Boost Supply of Anti-Obesity Drugs

Company warns of potential rationing and shortages as it prioritizes production of popular weight-loss drug Ozempic.

Novo Nordisk is investing over $8 billion in manufacturing to boost the supply of its popular anti-obesity drugs Ozempic and Wegovy.
The company will spend over $2.3 billion to expand a production facility in France, and over $6 billion to expand manufacturing capacity in Denmark.
Novo Nordisk warned it will have to ration Ozempic starter kits in Europe and reduce supplies of another diabetes drug, Victoza, in order to prioritize making more Ozempic.
The company predicts intermittent Ozempic shortages throughout 2024, while Victoza shortages could last until at least the second quarter of 2024.
The global market for anti-obesity drugs is expected to reach $100 billion a year by 2030, up from around $6 billion currently.